Multimedia Release -- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) -- First and Only Submental Contouring Injectable Drug

KYBELLA(TM) (deoxycholic acid) Injection Significantly Improves Submental Fullness, or "Double Chin"

| Source: KYTHERA Biopharmaceuticals, Inc. KYTHERA Biopharmaceuticals, Inc.

WESTLAKE VILLAGE, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH), issued a release on Wednesday, April 29, with the headline "Photo Release -- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) -- First and Only Submental Contouring Injectable Drug." The company is updating this release to include videos, which accompany the release issued yesterday.

Videos accompanying this release are available at:

http://www.globenewswire.com/newsroom/prs/?pkgid=32574

http://www.globenewswire.com/newsroom/prs/?pkgid=32575

http://www.globenewswire.com/newsroom/prs/?pkgid=32576


            




    

        

                
                    
                                

                    
                            

                    
                
                
                    
                                

                    
                            

                    
                
                
                    
                                

                    
                            

                    
                

        

    





        

            

                

                    
Tags

                            
                                BIOTECHNOLOGY
                            
                            
                                PHARMACEUTICALS
                            

                



        




    

        

        
Contact Data